Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) has received an average rating of “Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy rating. The average 12 month target price among brokers that have issued a report on the stock in the last year is $30.50.
A number of research firms have recently weighed in on KURA. HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Kura Oncology in a research report on Monday, August 12th. Stifel Nicolaus reduced their price objective on Kura Oncology from $28.00 to $26.00 and set a “buy” rating for the company in a report on Friday, August 9th. StockNews.com lowered Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, August 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research note on Friday, August 9th. Finally, Wedbush reissued an “outperform” rating and issued a $37.00 price objective on shares of Kura Oncology in a report on Friday, August 9th.
Check Out Our Latest Stock Analysis on KURA
Institutional Trading of Kura Oncology
Kura Oncology Stock Up 2.7 %
KURA stock opened at $21.06 on Tuesday. The stock has a market cap of $1.60 billion, a P/E ratio of -9.71 and a beta of 0.88. The company has a current ratio of 16.67, a quick ratio of 16.67 and a debt-to-equity ratio of 0.02. The stock’s fifty day simple moving average is $20.40 and its two-hundred day simple moving average is $20.67. Kura Oncology has a 1-year low of $7.41 and a 1-year high of $24.17.
Kura Oncology (NASDAQ:KURA – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. During the same quarter in the previous year, the company earned ($0.53) earnings per share. The company’s revenue was up .0% on a year-over-year basis. Analysts expect that Kura Oncology will post -2.56 EPS for the current year.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Featured Articles
- Five stocks we like better than Kura Oncology
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- Want to Profit on the Downtrend? Downtrends, Explained.
- MarketBeat Week in Review – 8/26 – 8/30
- Best Aerospace Stocks Investing
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.